Guipeng An

Prof. Dr. Guipeng An


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
XYXiaorong Yang
Xiaorong Yang
HCHui Chen
Hui Chen
DZDandan Zhang
Dandan Zhang
LSLin Shen
Lin Shen
GAGuipeng An
Guipeng An
SZShaohua Zhao
Shaohua Zhao
Aims: To estimate the spatiotemporal patterns in infective endocarditis (IE) burden along with its attributable risk factors at the national, regional, and global levels, which is essential to optimize the targeted prevention, clinical practice, and research. Methods and results: Based on all available data sources, the incidence, mortality, and disability-adjusted life years (DALYs) of IE in 204 countries and regions from 1990 to 2019 were reconstructed by Global Burden of Disease Study 2019 using the Cause of Death Ensemble model, spatiotemporal Gaussian process regression, and DisMod-MR 2.1. We depicted the epidemiological characteristics of IE in detail by gender, region, and age. Globally, 1 090 527 incident cases, 66 322 deaths, and 1 723 594 DALYs of IE were estimated in 2019. The age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) increased from 9.91 and 0.73 to 13.80 and 0.87 per 100 000 person-years over the past 30 years, respectively. ASIR were consistently more pronounced in higher socio-demographic index (SDI) regions. The leading ASMR in 2019 appeared in the High SDI region, with the largest increase in the past three decades. The age-specific burden rate of IE among people over 25 years old usually increased with age, and the annual increasing trend was more obvious for people over 60 years of age, especially in higher SDI regions. Conclusion: The incidence and mortality of IE have continued to rise in the past 30 years, especially in higher SDI regions. The patient population was gradually shifting from the young to the elderly.

31 July 2023 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
BWBaiqiang Wang
Baiqiang Wang
ZMZeyuan Mei
Zeyuan Mei
XGXiao Ge
Xiao Ge
YLYunyi Li
Yunyi Li
QZQuan Zhou
Quan Zhou
GAGuipeng An
Guipeng An
Background: The postoperative outcomes of transcatheter aortic valve replacement (TAVR) with the new generation of self-expanding valves (SEV) and balloon-expandable valves (BEV) remain uncertain. Methods: We conducted a meta-analysis based on randomized controlled trials (RCTs) and propensity score-matched (PSM) studies to evaluate the performance of the new generation TAVR devices, with a focus on Edwards SAPIEN 3/Ultra BEV, Medtronic Evolut R/PRO SEV, and Boston ACURATE neo SEV. Our primary endpoints were mortality and complications at both 30 days and one year post-operation. Results: A total of 4 RCTs and 14 PSM studies were included. Our findings showed no significant difference between SEV and BEV regarding 30-day and 1-year mortality rates. ACURATE SEV required less permanent pacemaker implantation (PPI) at 30-day as compared to SAPIEN BEV, while Evolut SEV required a higher rate of PPI than SAPIEN BEV. The incidence of stroke, major or life-threatening bleeding (MLTB), major vascular complications (MVC), coronary artery obstruction (CAO) and acute kidney injury (AKI) did not differ significantly between the two groups. SEV had a larger effective orifice area (EOA) and lower mean transvalvular gradients (MPG) compared to BEV. However, there was an increased risk of paravalvular leakage (PVL) associated with SEV. Conclusions: In terms of 30-day mortality, stroke, bleeding, MVC, AKI, CAO, and one-year mortality, there was comparability between the two valve types following TAVR. SEV was associated with better hemodynamic outcomes, except for a higher incidence of PVL. Compared to SAPIEN BEV, ACURATE SEV had a lower risk of PPI at 30 days, while Evolut SEV was associated with a higher risk of PPI. These findings underscore the importance of personalized valve selection.

18 March 2025 in Theranostics
Verified
Journal Article
Open access
PDF file
CGChenghu Guo
Chenghu Guo
XLXiaoling Liu
Xiaoling Liu
ZMZeyuan Mei
Zeyuan Mei
MCMeiling Chang
Meiling Chang
JLJiaqi Li
Jiaqi Li
GAGuipeng An
Guipeng An
Rationale: Calcific aortic valve disease (CAVD) is a progressive disorder characterized by aortic valve (AV) calcification and fibrosis. Despite advances in our understanding of CAVD pathogenesis, no drug has proven effective in preventing AV calcification. The aim of this study was to identify the key pathogenic genes in CAVD and elucidate mechanisms that may guide development of new targeted therapies.

4 April 2011 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
ZDZhe Dong
Zhe Dong
FAFengling An
Fengling An
TWTingting Wu
Tingting Wu
CZCheng Zhang
Cheng Zhang
MZMingxiang Zhang
Mingxiang Zhang
FAFengshuang An
Fengshuang An

16 March 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
KHKeqing Hu
Keqing Hu
XWXiaoqi Wang
Xiaoqi Wang
HHHongyan Hu
Hongyan Hu
ZXZhongyang Xu
Zhongyang Xu
JZJiaxing Zhang
Jiaxing Zhang
GSGuohai Su
Guohai Su
Intracoronary application of nicorandil can effectively reduce the myocardial no‐reflow (MNR) after percutaneous coronary intervention (PCI). We sought to investigate the mechanisms of nicorandil in preventing MNR, besides that of dilating the coronary microvasculature. A total of 60 patients undergoing PCI were enrolled and randomly divided into a nicorandil group and a control group. Before PCI, 2 mg of nicorandil or an equal volume of normal saline was injected into the coronary artery. Blood samples were collected before, 24 hours and 1 week after PCI and inflammatory cytokines were tested. In the control group, the expression of pro‐inflammatory cytokines was significantly increased, while the anti‐inflammatory cytokines were decreased 24 hours after PCI. In contrast, these changes were reversed in the nicorandil group, indicating that nicorandil regulated the inflammatory response induced by PCI. Then, proteomic analysis was performed to further elucidate the potential mechanisms. A total of 53 differentially expressed proteins (DEPs) were found 24 hours after PCI in the control group, and the changes of these relevant genes were reversed in the nicorandil group. These DEPs were significantly enriched in the inflammatory pathways. In conclusion, the intracoronary application of nicorandil before PCI can regulate the inflammatory responses induced by PCI, which might be an important mechanism of nicorandil in preventing MNR.

12 August 2025 in Scientific Reports
Verified
Journal Article
Open access
BWBaiqiang Wang
Baiqiang Wang
ZMZeyuan Mei
Zeyuan Mei
HYHong Yang
Hong Yang
WGWei Gao
Wei Gao
LMLianyue Ma
Lianyue Ma
GAGuipeng An
Guipeng An
The online version contains supplementary material available at 10.1038/s41598-025-14522-x.